Research is often lauded for finding life-saving treatments for diseases like cancer or diabetes. But consider the impact of preventing such illnesses from developing in the first place. It’s hard to describe the value of stopping illness or injury from happening. Yet that’s the goal of research on preventive care.
Most Kaiser Permanente Washington scientists study prevention, whether their work focuses on promoting health by influencing individual behavior, building sound prevention services into everyday clinical care, designing smart health coverage, or all three. By conducting their research at Kaiser Permanente Washington—which combines care and coverage—our researchers have access to data from a large, stable population over time, allowing them to discover which approaches to prevention work best.
Examples include research in areas such as:
A team of researchers at Kaiser Permanente Washington Health Research Institute (KPWHRI) produces reviews of scientific evidence that policymakers at the Centers for Medicare & Medicaid Services and the U.S. Preventive Services Task Force and others use in health care decision-making. We do this work as part of the Kaiser Permanente Research Affiliates Evidence-based Practice Center, one of 13 centers nationwide that are sponsored by the federal Agency for Healthcare Research and Quality.
We’re improving the safety and effectiveness of vaccines through clinical trials, and we’re monitoring how well each year’s new flu vaccines are working. In addition, we’re studying ways to better inform parents about the benefits and potential harms of childhood vaccines, to improve their uptake.
We’re working on several fronts to help ensure the safety of prescription drugs and other medical treatments. For example, we play a leading role in the Food and Drug Administration’s Sentinel program to monitor the safety of medical products through routinely collected electronic health care data. We’re exploring ways to improve the safety of prescribing opioid pain medications. And we often study the safety of drugs commonly used to prevent chronic conditions like heart disease, cancer, and depression.
Prevention also includes screening to detect disease before symptoms appear, to identify and treat disease at an earlier stage. Our research is improving the effectiveness of cancer screening programs so people get the appropriate tests when needed based on their particular risks. Our research is also aimed at improving clinical screening for behavioral risks such as smoking, suicidal thoughts, alcohol use disorders, and poor eating and exercise habits.
Our research in areas such as smoking cessation, healthy diet, and chronic illness care finds new ways to encourage individuals to adopt and maintain healthier lifestyles. At the same time, we’re exploring ways to reach large populations through the use of phone-based programs, websites, and mobile technologies.
Hamilton LK, Bradley KA, Matson TE, Lapham GT. Discriminative validity of a substance use symptom checklist for moderate-severe DSM-5 cannabis use disorder (CUD) in primary care settings. Drug Alcohol Depend Rep. 2024 Jul 15:12:100260. doi: 10.1016/j.dadr.2024.100260. eCollection 2024 Sep. PubMed
Boratyn VM, Pocobelli G, Atlas SJ, Clark CR, Feldman S, Kruse G, Marie McCarthy A, Rieu-Werden M, Silver MI, Santini NO, Tiro JA, Haas JS. Clinician-perceived barriers to cervical cancer screening before and during the COVID-19 pandemic at three US healthcare systems. Prev Med Rep. 2024 Jun 1;43:102783. doi: 10.1016/j.pmedr.2024.102783. eCollection 2024. PubMed
Phelan EA, Williamson BD, Balderson BH, Cook AJ, Piccorelli AV, Fujii MM, Nakata KG, Graham VF, Theis MK, Turner JP, Tannenbaum C, Gray SL. Reducing central nervous system-active medications to prevent falls and injuries among older adults: a cluster randomized clinical trial. JAMA Netw Open. 2024 Jul 1;7(7):e2424234. doi: 10.1001/jamanetworkopen.2024.24234. PubMed
Petrik AF, Rivelli JS, Firemark AJ, Johnson CA, Locher BW, Gille S, Najarian MJ, Varga AM, Schneider JL, Green B, Winer RL. A qualitative assessment of the acceptability of human papillomavirus self-sampling and informational materials among diverse populations. Cancer Med. 2024;13(14):e70033. doi: 10.1002/cam4.70033. PubMed
Hahn EE, Munoz-Plaza CE, Jensen CD, Ghai NR, Pak K, Amundsen BI, Contreras R, Cannizzaro N, Chubak J, Green BB, Skinner CS, Halm EA, Schottinger JE, Levin TR. Patterns of care following a positive fecal blood test for colorectal cancer: A mixed methods study. J Gen Intern Med. 2024 May 21. doi: 10.1007/s11606-024-08764-0. [Epub ahead of print]. PubMed
Paula Lozano, MD, MPHSenior Investigator; Director, ACT Center |
Katharine A. Bradley, MD, MPHSenior Investigator |
Jessica Chubak, PhDSenior Investigator |
Dori E. Rosenberg, PhD, MPHSenior Investigator |
Karen Wernli, PhDSenior Investigator |
Erin J. Bowles, MPHDirector, Collaborative Science |
Melissa L. Anderson, MSPrincipal Collaborative Biostatistician |
Paula R. Blasi, MPHCollaborative Scientist |
Joseph E. Glass, PhD, MSWAssociate Investigator |
Julie E. Richards, PhD, MPHAssistant Investigator |
Yu-Ru Su, PhDAssociate Biostatistics Investigator |
Annie Hoopes, MD, MPHActing Assistant Investigator |
Pamela A. Shaw, PhD, MSSenior Biostatistics Investigator |
Claire Allen, MPHManager, Collaborative Science |
Nicole M. Gatto, PhD, MPHPrincipal Collaborative Scientist |
Kelsey Stefanik-Guizlo, MPHCollaborative Scientist |
Theresa E. Matson, PhD, MPHCollaborative Scientist |
Meagan C. Brown, PhD, MPHAssistant Investigator |
Nora Henrikson, PhD, MPHAssociate Investigator |